The Effect of Edaravone Dexborneol Treatment After Intracranial Vascular Intervention on Inflammatory Factors and Oxidative Stress Level in Elderly Patients with Acute Ischemic Cerebrovascular Disease

Objective We aimed to explore the effects of applying edaravone dexborneol after intracranial vascular intervention on the levels of neuron-specific enolase (NSE), homocysteine (Hcy) and neurological function in elderly patients with acute ischemic cerebrovascular disease (AICVD).Methods The control group and study group were established. Serum levels of NSE, Hcy, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), and superoxide dismutase (SOD) activity were measured. Neurological function and hemorheological indices [plasma viscosity (PV), high-shear viscosity (HSV), low-shear viscosity (LSV)] were assessed. Adverse reactions and 6-month adverse outcomes were recorded.Results At 14 days postoperatively, the study group exhibited lower NSE, Hcy, IL-6, TNF-α, and MDA levels and higher SOD activity than the control group (all p < 0.05). NIHSS scores, PV, HSV, and LSV decreased in both groups at 7 and 14 days postoperatively (p < 0.05), with greater improvements in the study group (p < 0.05). The study group had a lower incidence of adverse outcomes (4.00% vs. 13.33%, p < 0.05).Conclusion Edaravone dexborneol after intracranial vascular intervention significantly reduces NSE and Hcy levels, mitigates inflammation and oxidative stress, improves neurological function and hemorheology, and lowers adverse outcome rates in elderly AICVD patients without increasing adverse reactions.